Nkarta Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Nkarta is gedaald met een gemiddeld jaarlijks percentage van -17%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 19.3%. De inkomsten zijn daalde met een gemiddeld percentage van 113.4% per jaar.

Belangrijke informatie

-17.0%

Groei van de winst

59.2%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	-113.4%
Rendement op eigen vermogen	-25.7%
Nettomarge	n/a
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Nov 20

Nkarta GAAP EPS of -$0.61

Aug 11

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Jun 09

Nkarta: A Promising Natural Killer Cell Play

May 20

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Aug 23

Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans

May 10

Nkarta gets greenlight from the FDA for NKX019 cancer study

Apr 28

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Jan 25

Opbrengsten en kosten

Hoe Nkarta geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:NKTX Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	0	-111	30	97
30 Jun 24	0	-108	29	94
31 Mar 24	0	-116	29	96
31 Dec 23	0	-118	30	97
30 Sep 23	0	-122	31	100
30 Jun 23	0	-125	31	102
31 Mar 23	0	-119	30	97
31 Dec 22	0	-114	28	91
30 Sep 22	0	-104	26	81
30 Jun 22	0	-98	24	75
31 Mar 22	0	-93	24	69
31 Dec 21	0	-86	23	63
30 Sep 21	0	-81	24	57
30 Jun 21	0	-72	22	66
31 Mar 21	0	-102	19	42
31 Dec 20	0	-91	15	36
30 Sep 20	0	-84	11	25
30 Jun 20	0	-73	8	0
31 Mar 20	0	-27	6	7
31 Dec 19	0	-21	5	0
31 Dec 18	7	0	3	0

Kwaliteitswinsten: NKTX is momenteel verliesgevend.

Groeiende winstmarge: NKTX is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: NKTX is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 17% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van NKTX over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: NKTX is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 16.6% ).

Rendement op eigen vermogen

Hoge ROE: NKTX heeft een negatief Return on Equity ( -25.67% ), omdat het momenteel verliesgevend is.

Nkarta Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Nkarta, Inc. to Report Q3, 2022 Results on Nov 09, 2022

First half earnings released

Recent updates

Price target decreased by 8.7% to US$15.83

Nkarta: Catalysts Ahead, But Competition In Cell Therapy Too (Rating Downgrade)

Price target decreased by 10% to US$17.33

We're Hopeful That Nkarta (NASDAQ:NKTX) Will Use Its Cash Wisely

Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

Nkarta, Inc. Announces Executive Appointments

Nkarta, Inc. Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

Nkarta, Inc. Appoints George Vratsanos as Board of Directors

Nkarta: A Look Into Q1 Results And Upcoming Catalysts

Nkarta, Inc., Annual General Meeting, Jun 13, 2024

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Nkarta, Inc. has completed a Follow-on Equity Offering in the amount of $240.10001 million.

New minor risk - Shareholder dilution

Nkarta: NK Cell Therapy Advancement On Two Fronts

Nkarta, Inc. has filed a Follow-on Equity Offering in the amount of $240.10001 million.

CEO, President & Director notifies of intention to sell stock

Nkarta: Possible Upside From H1 Update, If Positive

CEO, President & Director recently sold US$85k worth of stock

Price target increased by 7.7% to US$16.00

Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Nkarta, Inc. Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Price target decreased by 11% to US$17.38

We're Keeping An Eye On Nkarta's (NASDAQ:NKTX) Cash Burn Rate

New minor risk - Market cap size

Nkarta, Inc. Appoints Alyssa Levin as Chief Financial Officer

Nkarta, Inc. Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

New minor risk - Share price stability

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Nkarta, Inc. to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

Insufficient new directors

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Nkarta, Inc. Promotes David R. Shook to Chief Medical Officer

Price target decreased to US$30.36

Nkarta, Inc. Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation

High number of new directors

Nkarta, Inc. to Report Q3, 2022 Results on Nov 09, 2022

CEO, President & Director notifies of intention to sell stock

Nkarta GAAP EPS of -$0.61

Chief Financial & Business Officer exercised options and sold US$71k worth of stock

Nkarta, Inc. Announces Executive Changes

Price target decreased to US$43.56

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

Nkarta: A Promising Natural Killer Cell Play

Price target decreased to US$44.11

Nkarta, Inc. Announces Executive Changes

High number of new directors

Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs

Nkarta, Inc., Annual General Meeting, Jun 08, 2022

Nkarta, Inc. Appoints Angela M. Thedinga to its Board of Directors

Price target decreased to US$64.71

Nkarta, Inc. Presents NKX019 Trial in Progress Poster At the 2021 ASH Annual Meeting and Exposition

Insider notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

Insider exercised options and sold US$118k worth of stock

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Chief Scientific Officer exercised options and sold US$62k worth of stock

Nkarta, Inc.(NasdaqGS:NKTX) dropped from Russell 2500 Growth Index

CEO, President & Director notifies of intention to sell stock

Insider notifies of intention to sell stock

Chief Financial & Business Officer notifies of intention to sell stock

Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans

Chief Scientific Officer exercised options and sold US$62k worth of stock

Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies

Nkarta gets greenlight from the FDA for NKX019 cancer study

CEO, President & Director notifies of intention to sell stock

Chief Financial & Business Officer exercised options and sold US$246k worth of stock

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

New 90-day high: US$71.96

New 90-day high: US$35.74

New 90-day high: US$35.43